ArticleBlood advances2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.
Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.British journal of haematology · 2025Trial
- Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.Haematologica · 2026Review
- Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma.International journal of cancer · 2026Article
- The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE-FIRST study.HemaSphere · 2025Article
- Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.Future oncology (London, England) · 2025Article
- Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.Blood cancer journal · 2025Article
- Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas.Annals of hematology · 2025Review
- Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.Blood advances · 2024Review
- Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China.Annals of hematology · 2024Article
- Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.Blood advances · 2023Article
- Fungating nasal mass as a rare presenting manifestation of relapsed mantle cell lymphoma.BMJ case reports · 2023Article
- Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.Blood advances · 2023Article
- Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL.Blood advances · 2023Article
- A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.Blood advances · 2023Article
- Efficacy of front-line immunochemotherapy for transplant-ineligible mantle cell lymphoma: A network meta-analysis of randomized controlled trials.Cancer medicine · 2023Review
- Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.Blood advances · 2023Article
- Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis.Cancer medicine · 2023Article
- Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL.Blood advances · 2023Article
- Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?Current treatment options in oncology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
35 authors at 14 institutions in 2 countries.
Funding
Abstract
Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) after first-line therapy among 455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive disease during induction or POD within 6 months of diagnosis (n = 65; 14%); POD6-24, defined as POD between 6 and 24 months after diagnosis (n = 153; 34%); and POD>24, defined as POD >24 months after diagnosis (n = 237; 53%). The median overall survival from POD (OS2) was 1.3 years (95% confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95% CI, 6.2-NR) for those with POD>24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until POD was replicated in an independent cohort of 245 patients with relapsed MCL, with median OS2 of 0.3 years (95% CI, 0.1-0.5) for PRF/POD6, 0.8 years (95% CI, 0.6-0.9) for POD6-24, and 2.4 years (95% CI 2.1-2.7) for POD>24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.